{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:27:02Z","timestamp":1772126822901,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"49","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.vaccine.2013.09.038","type":"journal-article","created":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T23:26:16Z","timestamp":1381447576000},"page":"5897-5902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: Implication for post-exposure treatment"],"prefix":"10.1016","volume":"31","author":[{"given":"Amy B.","family":"Papaneri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wirblich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfred E.","family":"Marissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias J.","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.09.038_bib0005","first-page":"360","article-title":"Re-evaluating the burden of rabies in Africa and Asia","volume":"83","author":"Knobel","year":"2005","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0010","unstructured":"Rabies vaccines. WHO position paper. Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations=Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations 2007;82:425\u201335."},{"key":"10.1016\/j.vaccine.2013.09.038_bib0015","series-title":"WHO consultation on a rabies monoclonal antibody cocktail for rabies post exposure treatment","first-page":"23","year":"2002"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrmicro2260","article-title":"The cell biology of rabies virus: using stealth to reach the brain","volume":"8","author":"Schnell","year":"2010","journal-title":"Nature Reviews Microbiology"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/13550280590900418","article-title":"The role of immune responses in the pathogenesis of rabies","volume":"11","author":"Hooper","year":"2005","journal-title":"Journal of Neurovirology"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0030","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1586\/erv.10.105","article-title":"Experimental rabies vaccines for humans","volume":"9","author":"McGettigan","year":"2010","journal-title":"Expert Review of Vaccines"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0035","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1128\/JVI.02327-07","article-title":"The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread","volume":"82","author":"Pulmanausahakul","year":"2008","journal-title":"Journal of Virology"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0040","doi-asserted-by":"crossref","first-page":"e1002971","DOI":"10.1371\/journal.ppat.1002971","article-title":"Immune clearance of attenuated rabies virus results in neuronal survival with altered gene expression","volume":"8","author":"Gomme","year":"2012","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0045","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1135710","article-title":"Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G","volume":"315","author":"Roche","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0050","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev.med.58.061705.145053","article-title":"A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis","volume":"58","author":"de Kruif","year":"2007","journal-title":"Annual Review of Medicine"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0055","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1086\/500470","article-title":"Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin","volume":"193","author":"Goudsmit","year":"2006","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0060","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1016\/j.vaccine.2008.08.050","article-title":"First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity","volume":"26","author":"Bakker","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0065","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","article-title":"Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants","volume":"79","author":"Bakker","year":"2005","journal-title":"Journal of Virology"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0070","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/eji.200526134","article-title":"The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries","volume":"35","author":"Kramer","year":"2005","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0075","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1128\/JVI.79.8.4672-4678.2005","article-title":"Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis","volume":"79","author":"Marissen","year":"2005","journal-title":"Journal of Virology"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0080","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","article-title":"Efficient selection for high-expression transfectants with a novel eukaryotic vector","volume":"108","author":"Niwa","year":"1991","journal-title":"Gene"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0085","doi-asserted-by":"crossref","first-page":"9730","DOI":"10.1128\/JVI.00889-08","article-title":"PPEY motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity","volume":"82","author":"Wirblich","year":"2008","journal-title":"Journal of Virology"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0090","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/JVI.01309-10","article-title":"Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV","volume":"85","author":"Wirblich","year":"2011","journal-title":"Journal of Virology"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0095","doi-asserted-by":"crossref","first-page":"8122","DOI":"10.1073\/pnas.83.21.8122","article-title":"Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase","volume":"83","author":"Fuerst","year":"1986","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0100","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1128\/JVI.64.10.4907-4913.1990","article-title":"A fusion-defective mutant of the vesicular stomatitis virus glycoprotein","volume":"64","author":"Whitt","year":"1990","journal-title":"Journal of Virology"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0105","doi-asserted-by":"crossref","first-page":"10151","DOI":"10.1128\/JVI.00573-07","article-title":"Role of the cytoplasmic tail domains of Bunyamwera orthobunyavirus glycoproteins Gn and Gc in virus assembly and morphogenesis","volume":"81","author":"Shi","year":"2007","journal-title":"Journal of Virology"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0110","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1128\/JVI.77.20.10889-10899.2003","article-title":"Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome","volume":"77","author":"McGettigan","year":"2003","journal-title":"Journal of Virology"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0115","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1002\/j.1460-2075.1994.tb06739.x","article-title":"Infectious rabies viruses from cloned cDNA","volume":"13","author":"Schnell","year":"1994","journal-title":"EMBO Journal"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0120","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1073\/pnas.80.1.70","article-title":"Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus","volume":"80","author":"Dietzschold","year":"1983","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0125","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1128\/JVI.53.3.926-934.1985","article-title":"Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein","volume":"53","author":"Seif","year":"1985","journal-title":"Journal of Virology"},{"key":"10.1016\/j.vaccine.2013.09.038_bib0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/375247","article-title":"Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies","volume":"188","author":"Prosniak","year":"2003","journal-title":"Journal of Infectious Diseases"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T17:40:29Z","timestamp":1596649229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13012796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":26,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0264410X13012796"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: Implication for post-exposure treatment","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}